18F-氟昔洛韦PET/MRI用于新诊断高危前列腺癌分期及评估初始雄激素剥夺治疗反应的前瞻性单臂初步研究
前瞻性单臂初步研究纳入14例新诊断高危前列腺癌且常规分期影像阴性或不确定的患者,治疗前及手术后或ADT与放疗间行18F-氟昔洛韦PET/MRI。MRI与PET/MRI均准确识别全部14例前列腺内病灶,PET/MRI检出7例疑似淋巴结转移而MRI检出3例;ADT后前列腺内病灶SUVmean由4.5±1.1降至2.4±1.1(p=.008),可疑淋巴结SUVmax由5.5±3.7降至2.8±1.4(p=.03)。
要点
- MRI与18F-氟昔洛韦PET/MRI均准确识别全部14例前列腺内病灶。
- PET/MRI检出7例疑似淋巴结转移,MRI检出3例。
- ADT后前列腺内病灶及可疑淋巴结活性均下降。
关键影像表现/征象
- 活检证实的前列腺内病灶在全部14例中均被MRI和18F-氟昔洛韦PET/MRI准确识别。
- MRI检出3例疑似淋巴结转移,18F-氟昔洛韦PET/MRI检出7例疑似淋巴结转移。
- ADT后全部患者前列腺内病灶和/或所有可疑淋巴结活性均下降。
诊断标准与关键数值
- 由给定模态至少两名读者评为2分或3分的病灶视为阳性。
- 前列腺内病灶SUVmean治疗前为4.5±1.1(范围2.7-6.5),ADT开始后为2.4±1.1(范围0.0-3.6),p=.008。
- 可疑淋巴结SUVmax治疗前为5.5±3.7(范围2.8-12.7),治疗后为2.8±1.4(范围1.4-5.5),p=.03。
临床应用与阅片要点
- 鉴于18F-氟昔洛韦已获FDA批准且广泛可及,作者认为该研究结果可能在近期影响前列腺癌患者初始管理决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Despite advances in prostate cancer treatment, rates of biochemical recurrence remain high, relating to lack of detection of small-volume metastatic disease using conventional imaging for initial staging. OBJECTIVE. The purpose of this study was to assess the potential use of 18F-fluciclovine PET/MRI for initial staging of high-risk prostate cancer and evaluating response to androgen deprivation therapy (ADT). METHODS. This prospective clinical trial enrolled 14 men with newly diagnosed high-risk prostate cancer and negative or equivocal conventional staging imaging for metastatic disease between January 2018 and February 2019. All patients underwent pretreatment 18F-fluciclovine PET/MRI including multiparametric prostate MRI; 12 underwent 18F-fluciclovine PET/MRI after surgery or between ADT and radiotherapy. Confidence in identification of the primary intraprostatic lesion and nodal metastases was independently rated on a 0-3 Likert scale by three readers with nuclear medicine experience for 18F-fluciclovine PET/MRI and three readers with abdominal imaging experience for MRI alone. Findings scored as 2 or 3 by at least two readers of a given modality were considered positive. A single reader measured SUVmean, SUVmax, and volume of the MRI-defined intraprostatic lesion and SUVmax of suspicious lymph nodes on PET before and after initiation of ADT. Changes in SUV were analyzed using nonparametric Wilcox-on signed-rank tests. RESULTS. The biopsy-proven lesion in the prostate gland was accurately identified in all 14 patients on both MRI and 18F-fluciclovine PET/MRI. Suspected nodal metastases were detected in three patients on MRI and seven patients on 18F-fluciclovine PET/MRI. After ADT, all patients showed decreased activity within the intraprostatic lesion and/or all suspicious lymph nodes. The primary lesion SUVmean was 4.5 ± 1.1 (range, 2.7-6.5) before treatment and 2.4 ± 1.1 (range, 0.0-3.6) after initiation of ADT (p = .008). For suspicious lymph nodes, the pretreatment SUVmax was 5.5 ± 3.7 (range, 2.8-12.7) and the post-treatment SUVmax was 2.8 ± 1.4 (range, 1.4-5.5) (p = .03). CONCLUSION.18F-labeled fluciclovine PET/MRI shows potential utility in initial staging of high-risk prostate cancer and in evaluating response to ADT. CLINICAL IMPACT. Given the FDA approval and widespread availability of 18F-fluciclovine, the findings could have an impact in the immediate future in guiding initial management of patients with prostate cancer. TRIAL REGISTRATION. ClinicalTrials.gov NCT03264456.
引用
- Galgano SJ, McDonald AM, Rais-Bahrami S, et al. Utility of 18F-Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk Prostate Cancer and Evaluating Response to Initial Androgen Deprivation Therapy: A Prospective Single-Arm Pilot Study. AJR Am J Roentgenol. 2020. PMID: 33052718. doi:10.2214/AJR.20.24509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。